| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2022 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Jazz Pharmaceuticals PLC | 3 | Q2 2024 | 11.9% |
| Ascendis Pharma A/S | 3 | Q2 2024 | 8.3% |
| Cytokinetics Inc | 3 | Q2 2024 | 12.5% |
| Soleno Therapeutics Inc | 3 | Q2 2024 | 5.5% |
| Globus Medical Inc | 3 | Q2 2024 | 4.6% |
| Insmed Inc | 3 | Q2 2024 | 3.7% |
| ALX Oncology Holdings Inc | 3 | Q2 2024 | 2.6% |
| uniQure NV | 3 | Q2 2024 | 2.8% |
| Applied Therapeutics Inc | 3 | Q2 2024 | 2.9% |
| Immatics NV | 3 | Q2 2024 | 2.4% |
View Vestal Point Capital, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| SC 13G | 2024-02-13 |
| SC 13G | 2024-02-13 |
| SC 13G | 2024-02-13 |
View Vestal Point Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.